Prevalence and predictors of metabolic abnormalities in Chinese women with PCOS: a cross- sectional study by Rong Li et al.
Li et al. BMC Endocrine Disorders 2014, 14:76
http://www.biomedcentral.com/1472-6823/14/76RESEARCH ARTICLE Open AccessPrevalence and predictors of metabolic
abnormalities in Chinese women with PCOS: a
cross- sectional study
Rong Li1†, Geng Yu1†, Dongzi Yang2, Shangwei Li3, Shulan Lu4, Xiaoke Wu5, Zhaolian Wei6, Xueru Song7,
Xiuxia Wang8, Shuxin Fu9 and Jie Qiao1*Abstract
Background: Polycystic ovary syndrome (PCOS) is a common condition estimated to affect 5.61% of Chinese
women of reproductive age, but little is known about the prevalence and predictors in Chinese PCOS patients. This
study aimed to determine the prevalence and predictors of the metabolic abnormalities in Chinese women with
and without PCOS.
Methods: A large-scale national epidemiological investigation was conducted in reproductive age women (19 to
45 years) across China. 833 reproductive aged PCOS women, who participated in the healthcare screening, were
recruited from ten provinces in China. Clinical history, ultrasonographic exam (ovarian follicle), hormonal and metabolic
parameters were the main outcome measures.
Results: The prevalence of metabolic syndrome (MetS) as compared in PCOS and non-PCOS women from community
were 18.2% vs 14.7%, and IR (insulin resistance) were 14.2% vs 9.3% (p < 0.001) respectively. After adjusting for age, the
indicators (central obesity, hypertension, fasting insulin, SHBG, dyslipinaemia) for metabolic disturbances were significantly
higher in PCOS than in non-PCOS groups. Using multivariate logistic regression, central obesity and FAI were risk factors,
while SHBG was a protective factor on the occurrence of Mets and IR in PCOS women (OR: 1.132, 1.105 and 0.995).
Conclusions: The risk factors of the metabolic syndrome and insulin resistance were BMI and FAI for PCOS women,
respectively. The decrease of SHBG level was also a risk factor for insulin resistance in both PCOS and metabolic
disturbance.
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Polycystic ovary syndrome (PCOS) is a common condition
estimated to affect 5.6% of Chinese women of reproduct-
ive age [1,2]. PCOS is associated with reproductive and
metabolic disturbances [3]. Based on the Adult Treatment
Panel III criteria [4], the prevalence of metabolic syn-
drome (MetS) has been previously reported to be 1.6% [5],
8.2% [6] and 43% [7] in Czech, Italian and US women with
PCOS, and 24.9% in Chinese Hongkong women [8]. The
prevalence of MetS in PCOS women showed a marked* Correspondence: jie.qiao@263.net
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unless otherwise stated.variation between countries and ethnic groups, probably
due to differences in diet, lifestyle and genetic factors. In
addition, it was also associated with the investigated popu-
lation. A meta-analysis supported a greater prevalence of
glucose intolerance (IGT), Types 2 diabetes (DM2) and
the metabolic syndrome in women with PCOS as com-
pared with women without PCOS [9]. The odds of meta-
bolic disturbance were two to four times as high in PCOS
women [9]. The predisposition of PCOS women to
various metabolic disturbances, including obesity, IGT,
atherogenic dyslipidaemia and hypertension, increased in
the long-term risk of DM2 and cardiovascular disease
(CVD), which indicated that PCOS carried significant
public health implication [10]. Recent evidence also indi-
cated more frequent CVD death in women with PCOShis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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economic costs of PCOS can be attributed to DM2 in the
USA, highlighting the need for prevention of long term
complications through appropriate screening, diagnosis
and intervention for PCOS [10].
Insulin resistance (IR) is the most likely the pathogenic
link between PCOS and MetS. The co-morbidities associ-
ated with IR are common to both conditions. All surrogate
markers of reduced insulin sensitivity have consistently
been found in women with concomitant PCOS and MetS
compared to those without MetS, even after controlling for
Body Mass Index (BMI) [11]. Some evidence suggested that
women with PCOS had a greater predisposition to obesity.
The increased risk of MetS and IR in women with
PCOS has raised further interest in identifying the pre-
dictors for MetS and IR in these women. The objective
of this study was to investigate the prevalence of the
metabolic syndrome in PCOS women in China, and de-
tect the predictive risk factors in metabolic disturbances
in order to find an effective tool to screen for potential
CVD risk factor in Chinese women with PCOS.
Methods
Anthropometric and metabolic measures were performed
for women who participated in the epidemiological study
of PCOS around China. All participants were systematic-
ally evaluated and written informed consent was obtained
from all participants. The study route was in the flow-
chart, Figure 1.
The diagnosis of PCOS was based on Rotterdam-PCOS
criteria [12]. According to these criteria, PCOS were diag-
nosed if at least two of the following criteria were present:Figure 1 Route diagram of the present prevalence study.oligo/amenorrhoea, clinical or biochemical hyperandro-
genism and PCO on ultrasonography. Other etiology that
could mimic PCOS, like Cushing syndrome, late onset ad-
renal hyperplasia or androgen producing neoplasm had to
be excluded.
Oligomenorrhea and amenorrhea were defined as hav-
ing fewer than 8 menstrual cycles per year, or the ab-
sence of 3 to 6 consecutive menstrual cycles per year.
Clinical hyperandrogenism was defined as the presence
of hirsutism (Ferriman-Galwey score ≥6, no oral contracep-
tive pills were used within three months). Biochemical
hyperandrogenism was present if testosterone >2.8 nmol/L
or androgen > 10.8 nmol/L, which were the normal range
of 95% percentile in the population in our laboratory. PCO
was defined as the presence of at least one ovary with 12 or
more follicles measuring 2-9 mm in diameter.
MetS was defined according to modified NCEP ATP III
guidelines 2005 [13]. MetS was diagnosed if at least three
of the following five measures were present: (i) waist cir-
cumference ≥ 80 cm, (ii)serumtriglyceride ≥ 1.7 mmol/l,
(iii) serum high-density lipoprotein (HDL)-cholesterol <
1.3 mmol/l or the use of lipid lowering medication, (iv)
blood pressure ≥130/85 mmHg or the use of anti-
hypertensive (v) fasting plasma glucose ≥5.6 mmol/l.
IR was evaluated by using the homeostatic model as-
sessment (HOMA-IR: (fasting insulin × fasting glucose)/
22.5) and 2.69 was selected as the cut-off point [14].
A large-scale national epidemiological investigation was
conducted in women of reproductive age (19 to 45 years)
from the top ten provinces and municipalities in China [1].
Ten geographically distributed provinces/municipalities con-
tained the major residential population from 30 provinces of
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both rural and urban communities (1:1). Ten provinces were
chosen from all 30 provinces according to geographically
distributed, then used a multi-layer, stratified sampling
method from city or district to communities. A total of 5163
women underwent the investigation from 2008 to 2009.
Only 3565 participants completed the panel of physical
examination, ultrasound and laboratory data for the classifi-
cation of PCOS. Twenty interviewers, gynaecologists and
ultrasonographcis were trained to administrate the standard-
ized questionnaire and conduct, physical examination and
ultrasound following the same Standard Operating Proced-
ure. MetS and IR, the main issue, were considered for ana-
lysis. Other disorders such as nonclassical congenital and
renal hyperplasia, thyroid dysfunction, and hyperprolactine-
mia were excluded by examining medical histories and hor-
mones tests, and we deemed the abnormality for prolactin
(PRL ≥25 ng/ml) and thyroid dysfunction (TSH <0.5 mU/
Lor >4.78 mU/L), according to the reference value. Other
exclusionary criteria included unsolved medical conditions,
pregnancy and the use of medications known or suspected
to affect fertility or metabolic function with 90 days of the
study entry was prohibited. This study was approved by the
Ethics Committee of Peking University Third Hospital
and conducted based on guidelines of the institutional
review boards in each of the participating centres. All
subjects provided written informed consent.
Physical examination, ultrasound and laboratory
assessment
Blood pressure was obtained in sitting patients after a
five-minute rest. Waist circumference was measured in
the standing position, halfway between the lower ribs
and the superior anterior iliac spine of the pelvic. The
hip circumference was measured at the level of the pubic
symphysis. Hirsutism was established by using the modi-
fied Ferriman-Galwey score [15]. Transvaginal ultrason-
ography was performed by the investigators to detect
PCO. Height and body weight were measured, and BMI
value were calculated. The BMI values were classified fol-
lowing the established criterion, that is normal (23 kg/m2 ≤
BMI < 25 kg/m2), overweight (25 kg/m2 ≤BMI 30 < kg/m2)
and obese (BMI ≥ 30 kg/m2) obese in Asian [16].
Laboratory tests
All blood samples were collected in the morning after
fasting for at least 8 hours. Fasting plasma glucose (FPG)
was measured by using finger stick blood glucose
method (Roche ACCU-CHEK). Venous blood sample
were collected and were immediately centrifuged, then
the serum was separated and frozen at −20°C until
assayed. All blood samples’ test was done in Peking
University Third Hospital. Fasting insulin (FI), SHBG, total
testosterone (TT), androstenedione (A), PRL and TSHwere assessed by chemiluminescence under the Immulite
1000 (DPC, USA). Manufacturer’s instructions were
followed for preparation, set-up, dilutions, adjustments,
assay, and quality control procedures. For all measure-
ments, the inter-assay coefficient of variation was less than
10%, while the intra-assay variation was less than 15%.
Fasting cholesterol, triglyceride (TG), low-density lipopro-
tein (LDL) and high-density lipoprotein (HDL) were mea-
sured by dry slide enzymatic colorimetric assay. The free
androgen index (FAI) was calculated using the formula
[TT (nmol/L) × 100/SHBG (nmol/L)].
Statistical analysis
All analyses were performed by using Statistical Product
and Service Solutions (SPSS) (version 13.0, spss inc.,
Chicago, IL, USA). Continuous variables were presented
as mean ± SD or median (interquartile range), and ana-
lysed using independent sample t-test for normally dis-
tributed data or Mann–Whitney U-test for skewed data.
Categorical variables were expressed as proportion (per-
centage) and analysed by X2 or Fisher’s exact tests as ap-
propriate. Multivariate logistic regression was used to
examine independent predictors of MetS and IR. The re-
sults were expressed as age and BMI adjusted odds ratio
(OR) with 95% confidence interval (CI) or two sided p-
value. Baseline characteristics of the different PCOS
phenotype and controls were evaluated by analysis of
variance. Proportion was compared using the chi-square
test. Univariate logistic regression analysis was applied
to qualify the association between several clinical and la-
boratory variables, and the presence of the metabolic
disturbances. Variables that appear to be associated were
further analysed using multivariate logistic regression ana-
lysis with backwards stepwise selection. Statistical signifi-
cance was considered present if the P-value was <0.05.
Results
Prevalence of the metabolic syndrome and insulin
resistance in different phenotype PCOS in community
The prevalence of the metabolic syndrome and insulin re-
sistance were 19.1% (159/833) and 14.2% (118/833) in
women with PCOS. Table 1 showed the prevalence of
MetS in different PCOS phenotype subgroups was similar
(Table 1).
Clinical and biochemical characteristics of the PCOS and
non-PCOS
Of the 3,565 women screened, 833 were diagnosed as
PCOS according to Rotterdam-PCOS criteria, and 2,732
were non-PCOS population. Compared women without
PCOS, those with PCOS were younger, but there was no
difference in central obesity as measured by Waist to hip
ratio (WHR). However, since age and central obesity
were closely correlated, the indicators for central obesity
Table 1 Prevalence of MetS and IR in different phenotypes in PCOS women
IM + HA + PCOM IM +HA HA + PCOM IM + PCOM P-value
Number in community 28.69% (239/833) 18.97% (158/833) 37.33% (311/833) 15.01% (125/833) <0.001
MetS(ATPIII2005) in community 20.5% (49/239) 17.1% (27/158) 18.6% (58/311) 20.0% (25/125) 0.87
IR in community 16.7% (40/239) 13.9% (22/158) 12.9% (40/311) 12.8% (16/125) 0.20
IM: irregular menstruation; HA:hyperandrogenism; PCOM: pco morpholity.
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PCOS when adjusted for ages.
In addition, T, A, FAI were significantly higher, while
SHBG was lower in PCOS than non-PCOS women.
After controlling for age and BMI, that was no differ-
ence in blood pressure, cholesterol, HDL, LDL, FPG, FI,
HOMA-IR between the two groups, with the exclusion
of TG which was higher in PCOS.
Prevalence of the metabolic syndrome and insulin
resistance in PCOS and non-PCOS women
The prevalence of MetS (ATPIII2005) was 19.1% (159/833)
and 14.7% (401/2732) (P < 0.001) respectively, in PCOS
women and non-PCOS women. In addition, 34.1, 18.6,
13.0, 4.8, 1.3% of women with PCOS had at least one, two,
three, four or five components of Mets (ATPIII2005), re-
spectively. The frequency of each component of metabolicTable 2 Comparison of women with and without PCOS
PCOS Non-PCOS P-value
No. of subject 833 2,732
Age 29.1 ± 5.4 32.3 ± 6.1 <0.001
BMI 22.3 ± 3.9 22.2 ± 3.2 0.33
Weight 56.8 ± 10.7 56.1 ± 8.8 0.09
Height 159.4 ± 5.1 159.0 ± 5.5 0.04
Waistline 75.9 ± 10.5 75.6 ± 9.1 0.37
WHR 0.83 ± 0.07 0.83 ± 0.07 0.59
SBP 111.3 ± 13.9 111.6 ± 13.8 0.57
DBP 73.2 ± 10.2 73.1 ± 9.8 0.92
FPG 5.2 ± 1.0 5.1 ± 1.0 0.04
FI 4.0 (2.0-7.4) 3.4 (2.0-6.0) <0.001
HOMA-IR 0.9 (0.5-1.7) 0.8 (0.5-1.4) <0.001
Cholestrol 4.5 ± 1.0 4.5 ± 1.0 0.21
HDL 1.4 ± 0.4 1.4 ± 0.3 0.08
LDL 2.3 ± 0.7 2.3 ± 0.7 0.29
SHBG 50.6 (34.5-70.9) 59.4 (42.3-81.0) <0.001
FAI 3.7 (2.3-6.1) 2.1 (1.4-3.4) <0.001
TG 1.0 (0.7-1.5) 1.0 (0.7-1.4) 0.83
T 1.9 (1.4-2.5) 1.3 (0.8-1.8) <0.001
A 12.5 (10.2-15.2) 8.3 (6.2-10.5) <0.001
Comments: Data were presented as means ± SD, proportion (%) or median (inter-qu
or Mann–Whitney U-test as appropriated. BP, blood pressure; TG, triglycerides; HDL
cholesterol; FPG, fasting plasma glucose; FI, fasting insulin.syndrome population, in decreasing order, was reduced
HDL-C (85.9%), central obesity (84.8%), increased TG
(63.4%), increased fasting glucose (55%), and hypertension
(45.7%).
The prevalence of IR was 14.2% (118/833) and 9.3%
(254/2732) respectively, with P <0.001. After adjusted
for age and BMI, the prevalence of IR and MetS between
the two groups was still significantly different (Table 2).
We performed stratified analysis, by age and weight
category, since age and BMI were well known confound-
ing factors for MetS (Figure 2 and Figure 3). As was ex-
pected, the prevalence of MetS increased with increasing
age and was significantly higher in PCOS than non-PCOS
women in all age groups. IR was also significantly higher
with age in PCOS. When compared the prevalence of
MetS after stratification into subgroups of normal-weight



















artile range), and analysed by independent sample t-test, X2/fisher’s exact tests,
-C, high-density lipoprotein cholesterol; LDL-C, low-density lipopreotein
Figure 3 BMI-stratified prevalence of MetS in PCOS. Diagnosis of
MetS based on the modified Adult Treatment Penal III (ATP2005).
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obese II group had 13–16 fold risk of MetS than normal
weight woman, irrespective of the presence of PCOS. In
the four groups, the prevalent differences of PCOS and
non-PCOS women were not significant except obese I
group (p = 0.006) (Figure 3).
Characteristics of PCOS women with and without
metabolic syndrome
As shown in Table 3, women with the metabolic syn-
drome were older and more obese. They also had lower
SHBG concentrations, higher FAI and reduced insulin
sensitivity as manifested by greater HOMA-IR and higher
fasting insulin concentrations than those without MetS.
There were no significant differences in serum total tes-
tosterone or androgen between those PCOS women with
and without MetS. The proportion of HA, IM, PCOM
were not significantly different between PCOS woman
with MetS and without MetS.
Predictors of MetS and IR by using multivariate logistic
regression analysis
Multivariate logistic regression was also performed to
examine the independent predictors of Mets and IR in
all women with and without PCOS. For women with
PCOS, BMI (OR: 1.420, 95% CI 1.328-1.518) and FAI
(OR: 1.132, 95% CI 1.037-1.236) were risk factors for
MetS, while SHBG (OR: 0.995, 95% CI 0.990-1.000) was
protective factor. For women without PCOS, the risk
factor was BMI (OR: 1.381, 95% CI 1.324-1.440).
Predictive factors for the presence of IR in women with
PCOS were BMI (OR: 1.211, 95% CI 1.147-1.279), A (OR:
1.067 95% CI 1.022-1.114) and FAI (OR: 1.105, 95% CIFigure 2 Age-stratified prevalence of MetS in PCOS. Diagnosis of
MetS based on the modified Adult Treatment Penal III (ATP2005).1.049-1.165), while the protective factor was SHBG (OR:
0.985, 95% CI 0.976-0.994). For women without PCOS,
predictive factors were BMI (OR: 1.186, 95% CI 1.140-
1.234), and FAI (OR: 1.120, 95% CI 1.053-1.193) (Table 4).
Discussion
In the present study, a large-scale national epidemio-
logical investigation was conducted in reproductive age
women (19 to 45 years) across China, and total 833 re-
productive aged PCOS women who were accordance
with the established criterions participated from ten
provinces in China. Compared with non-PCOS patients,
we found that obesity and FAI were both risk factors for
PCOS women, while SHBG acted as a protective factor
role on the occurrence of Mets and IR in PCOS women.
Prevalence of metabolic disturbances in PCOS and
non-PCOS women
The consequences of the polycystic ovary syndrome ex-
tended beyond the reproductive axis; as women with
PCOS are at substantial risk for the metabolic syndrome.
Also, previous studies indicated that 30–40 percent
women with PCOS have impaired glucose tolerance, and
as many as 10 percent have type 2 diabetes by their
fourth decade [17,18].
In agreement with the previous studies, we demon-
strated that a higher prevalence of MetS (ATPIII2005) and
IR in women with PCOS than those without PCOS. After
controlling for the age and BMI, the difference was still
significant, indicating PCOS women had a higher risk of
metabolic disturbance compared to the controls.
The prevalence of MetS and IR were significantly
higher in PCOS women than non-PCOS women in gen-
eral population of China. The PCOS phenotype had no
Table 3 Comparison of PCOS women with MetS and without MetS
Non-Mets2005 MetS2005 P-value Age and BMI adjusted p-value
No. of subject 674 159
Age 28.7 ± 5.3 30.1 ± 5.5 <0.001
BMI 21.5 ± 2.8 25.9 ± 3.7 <0.001
Weight 54.0 ± 8.4 68.3 ± 11.7 <0.001 0.44
Height 159.4 ± 5.0 159.7 ± 5.6 0.49 0.03
Waistline 73.0 ± 8.3 88.0 ± 10.2 <0.001 <0.001
WHR 0.81 ± 0.06 0.89 ± 0.06 <0.001 <0.001
SBP 108.5 ± 11.3 123.2 ± 17.0 <0.001 <0.001
DBP 71.1 ± 8.7 80.8 ± 11.7 <0.001 <0.001
FG 5.1 ± 0.9 5.6 ± 1.2 <0.001 <0.001
FI 3.5 (2.0-5.9) 8.6 (4.7-14.2) <0.001 <0.001
HOMA-IR 0.8 (0.5-1.3) 2.2 (1.2-3.7) <0.001 <0.001
Cholesterol 4.5 ± 1.0 4.6 ± 0.9 0.36 0.17
HDL 1.4 ± 0.3 1.1 ± 0.2 <0.001 <0.001
LDL 2.3 ± 0.8 2.4 ± 0.7 0.09 0.47
SHBG 55.4 (40.6-75.6) 27.9 (19.8-45.5) <0.001 <0.001
FAI 3.3 (2.1-5.2) 6.4 (3.4-10.2) <0.001 <0.001
TG 0.9 (0.7-1.2) 2.0 (1.3-2.5) <0.001 <0.001
T 1.9 (1.4-2.6) 1.9 (1.3-2.5) 0.39 0.13
A 12.4 (10.2-15.3) 12.7 (10.4-14.9) 0.94 0.56
IM 62.5% (421/674) 63.5% (101/159) 0.44 0.43
HA 85.2% (574/674) 84.3% (134/159) 0.43 0.76
PCOM 80.6% (543/674) 83.0% (132/159) 0.28 0.23
Comments: Data were presented as means ± SD, proportion(%) or median(inter-quartile range), and analysed by independent sample t-test, X2/fisher’s exact tests,
or Mann–Whitney U-test as appropriated. BP, blood pressure; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C low-density lipopreotein
cholestrol. FPG, fasting plasma glucose; FI, fasting insulin: IM: irregular menstruation HA:hyperandrogenism PCOM: pco morpholity.
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study concluded that obesity was strongly associated
with MetS in adolescent women, whether they had
PCOS or not [19]. Obesity appeared to be closely associ-
ated with PCOS. For example, in the United States,
more than half of the patients with PCOS are either
overweight or obese [20]. Our data also showed theTable 4 Predictors of MetS and IR by using multivariate
logistic regression analysis
OR 95.0% CI P
PCOS/ MetS BMI 1.420 1.328-1.518 0.000
FAI 1.132 1.037-1.236 0.006
SHBG 0.995 0.990-1.000 0.086
Non-PCOS/ MetS BMI 1.381 1.324-1.440 0.000
PCOS/ IR BMI 1.211 1.147-1.279 0.000
A 1.067 1.022-1.114 0.011
FAI 1.105 1.049-1.165 0.000
Non-PCOS/IR BMI 1.186 1.140-1.234 0.000
FAI 1.120 1.053-1.193 0.000PCOS women are more obese than control, but the per-
centage of overweight/obesity was not significantly dif-
ferent between PCOS (33.9%) women and Non-PCOS
women (34.4%). Our study demonstrated that the meta-
bolic disturbance was occurred more often in overweight
and obese women. It was interesting that SHBG level
was significantly lower in PCOS women compared with
non-PCOS women, as well as SHBG level was also sig-
nificantly lower in MetS than in non-MetS. Since the
SHBG had correlation to the IR [21]. This study indi-
cated that SHBG was a well- established marker of insu-
lin resistance in diabetics [22], and low levels had been
reported in adolescent girls with premature pubarche
(who were known to be at risk for PCOS and insulin re-
sistance) [23]. Our results regarding the SHBG were pro-
tective factor, which was not reported by other research.
We interpreted that the variation in SHBG levels might
mostly result from the effects of IR/hyperinsulinemia
upon hepatic SHBG production. Thus a low level of
SHBG might serve as another marker of insulin resist-
ance, and a key factor during the pathogenesis of both
PCOS and MetS.
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abnormalities in PCOS
The relationship between hyperandrogenaemia and meta-
bolic abnormalities is controversial. Apridonidze et al. de-
scribed a higher prevalence of hyperandrogenaemia in
women with concomitant PCOS and MetS [7], others
study concluded that DHEAS correlated inversely with ar-
terial structure, suggesting possible cardio-protective ef-
fects of endogenous DHEAS in women with PCOS [24].
However, our data, similar studies from Dokras et al. [11]
and L.P. Cheung et al. [8], all failed to demonstrate any
significant differences in serum concentrations in total
testosterone and androgen between those PCOS women
with or without MetS. Therefore, it appeared that hyper-
androgenaemia, by itself, may not directly contribute to
the development of MetS in women with PCOS.
Considering the higher prevalence of insulin resistance
in the PCOS women, we analyzed the high risk factors
including BMI, testosterone, androgen, SHBG and FAI
as the predictors of IR in PCOS women.
Currently, it was shown that lipid abnormalities and
hyperinsulinaemia persisted despite suppression of an-
drogens with GnRH agonists in hirsute hyperandrogenic
women [25]. The recognition of the role of insulin resist-
ance, rather than hyperandrogenism, as the main culprit
in the pathogenesis of MetS in PCOS had an important
therapeutic implication. Due to the higher prevalence of
MetS and IR in the PCOS women, and serious complica-
tions such as CVD and DM2, it was also important to
treat these diseases beyond the fertility aspects.
The strength of the study was the large scale investiga-
tion, and all the women participated were recruited from
the general population. AS compared with other studies
on MetS in PCOS, most PCOS women were recruited
from the hospital or clinics, which might contribute to
potential selection bias and over estimated the risk of
MetS and IR in the PCOS cohort. However, there were
also several limitations of this study. We measured total
testosterone concentration and FAI, which might be a
less sensitive marker for hyperandrogenism than free
testosterone levels. . In the present study, being the first
large scale study in general population, might provide
valuable insight towards better understanding of IR and
MetS profiles in PCOS women in China.
Conclusion
In conclusion, the prevalence of MetS and IR were signifi-
cantly higher in PCOS women than non-PCOS women in
Chinese community, and their risk factors were BMI and
SHBG. Moreover FAI was also one of risk effects on the
insulin resistance in PCOS women since the hyperandro-
ginaemia. The present study facilitated the understand for
PCOS pathological characteristics, and was helpful to seek
the new target for treatment.Abbreviations
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